Related Experiment Video
Updated: Jun 2, 2026

Mechanism of Regulation of Adipocyte Numbers in Adult Organisms Through Differentiation and Apoptosis Homeostasis
Published on: June 3, 2016
Follistatin and follistatin like-3 differentially regulate adiposity and glucose homeostasis
Melissa L Brown1, Lara Bonomi, Nathan Ungerleider
1Pioneer Valley Life Science Institute, University of Massachusetts Amherst, Springfield, Massachusetts, USA.
Abstract:
Transforming growth factor-β superfamily ligands, including activin and myostatin, modulate body composition, islet function, and glucose homeostasis. Their bioactivity is controlled by the antagonists follistatin (FST) and FST like-3 (FSTL3). The hypothesis tested was that FST and FSTL3 have distinct roles in regulating body composition, glucose homeostasis, and islet function through regulation of activin and myostatin bioactivity. Three genetic mutant mouse lines were created. FSTL3 knockout (FSTL3 KO), a mouse line producing only the FST288 isoform (FST288-only) and a double mutant (2xM) in which the lines were crossed. FST288-only males were lighter that wild-type (WT) littermates while FSTL3 KO and 2xM males had reduced perigonadal fat pad weights. However, only 2xM mice had increased whole body fat mass and decreased lean mass by quantitative nuclear magnetic resonance (qNMR). Fasting glucose levels in FSTL3 WT and KO mice were lower than FST mice in younger animals but were higher in older mice. Serum insulin and pancreatic insulin content in 2xM mice was significantly elevated over other genotypes. Nevertheless, 2xM mice were relatively insulin resistant and glucose intolerant compared to FST288-only and WT mice. Fractional islet area and proportion of β-cells/islet were increased in FSTL3 KO and 2xM, but not FST288-only mice. Despite their larger size, islets from FSTL3 KO and 2xM mice were not functionally enhanced compared to WT mice. These results demonstrate that body composition and glucose homeostasis are differentially regulated by FST and FSTL3 and that their combined loss is associated with increased fat mass and insulin resistance despite elevated insulin production.
Insights
Follistatin (FST) and FSTL3 differentially regulate body composition and glucose homeostasis. Their combined loss in mice increases fat mass and insulin resistance, despite higher insulin levels and larger islets.
Area of Science:
- Endocrinology
- Metabolism
- Molecular Biology
Background:
- Transforming growth factor-β (TGF-β) superfamily ligands, including activin and myostatin, are key regulators of body composition, islet function, and glucose homeostasis.
- The bioactivity of these ligands is tightly controlled by antagonists follistatin (FST) and FST-like 3 (FSTL3).
Purpose of the Study:
- To investigate the distinct roles of FST and FSTL3 in regulating body composition, glucose homeostasis, and islet function.
- To determine how FST and FSTL3 modulate activin and myostatin bioactivity in vivo.
Main Methods:
- Generation of three distinct mouse genetic models: FSTL3 knockout (FSTL3 KO), a line expressing only the FST288 isoform (FST288-only), and a double mutant (2xM).
- Assessment of body composition using quantitative nuclear magnetic resonance (qNMR).
- Evaluation of glucose homeostasis, insulin levels, and pancreatic islet morphology and function across genotypes.
Main Results:
- FST288-only males were lighter than wild-type (WT) mice; FSTL3 KO and 2xM males exhibited reduced perigonadal fat pad weights.
- 2xM mice displayed increased whole-body fat mass and decreased lean mass, alongside elevated fasting glucose in older animals.
- Despite increased serum insulin and pancreatic insulin content, 2xM mice showed insulin resistance and glucose intolerance. Islet size and β-cell proportion increased in FSTL3 KO and 2xM mice, but function was not enhanced.
Conclusions:
- FST and FSTL3 play differential roles in regulating body composition and glucose metabolism.
- Combined loss of FST and FSTL3 leads to increased adiposity and insulin resistance, characterized by compensatory hyperinsulinemia and altered islet structure without functional improvement.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Regulation of Food Intake
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
TGF - β Signaling Pathway
